Efficacy and Safety of SCT200 in Patients With Advanced Squamous Non-small Cell Lung Cancer
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of recombinant anti-EGFR
monoclonal antibody（SCT200）in patients with advanced squamous non-small cell lung cancer
treated after failure of Two chemotherapy regimens (including Platinum-based drugs).